Graftys SA Receives FDA Clearance for Injectable Bone Filler

Graftys SA, a developer of synthetic bone void substitute products, announced it received 510(k) premarket clearance notification from the U.S. Food and Drug Administration for its Graftys Quickset injectable, fast-setting bone void filler, according to a Graftys news release.

Advertisement

The Aix-en-Provence, France-based company now offers a range of resorbable, highly injectable phosphocalcic cements, which includes slower setting Graftys HBS, to address a wide array of clinical needs, according to the release.

Read the Graftys release on Quickset bone filler (pdf).

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.